Concomitant sentinel lymph node biopsy leading to abbreviated systematic lymphadenectomy in a patient with primary malignant melanoma of the vagina
© Ishida et al.; licensee Springer. 2015
Received: 8 September 2014
Accepted: 22 December 2014
Published: 28 February 2015
Primary malignant melanoma of the vagina is an extremely rare disease affecting 3% of patients with malignant vaginal tumors. It is rare compared to primary malignant melanoma of the skin and its prognosis is unfavorable even in patients with Stage I disease. Here, we report a case of primary malignant melanoma of the vagina and discuss our experience with regard to previously published literature.
The patient was a 59-year-old female with 2 prior pregnancies and child births. She was examined by a local doctor for swelling of the genitalia, and a 1.8 × 1.0 cm large tumor was detected on the left side of the vaginal wall. A biopsy indicated leiomyosarcoma, and she was referred to our hospital. The tumor was resected, and histopathology of the resected sample confirmed the diagnosis of malignant melanoma based on a positive surgical margin. Additional courses of treatment included left inguinal sentinel lymph node biopsy using an isotope and extended vaginectomy. Although the sentinel node was negative, we performed a modified radical hysterectomy and left vaginectomy during the third operation because the surgical margin was positive. We could not confirm whether the lesion in the extracted sample was malignant, and the final diagnosis was primary malignant melanoma of the vagina T4bN0M0 Stage IIc (UICC 2009). Postoperative adjuvant therapy consisted of 6 cycles of DAV-Feron therapy (dacarbazine, ACNU, vincristine, IFN- β). After 5 months of postoperative adjuvant therapy, a 2 cm single lung metastasis was detected in the lower left lung. We performed a laparoscopic lower left lobectomy and are planning additional chemotherapy.
Discussion and evaluation
Currently, surgical resection has the highest probability of improving the prognosis of patients when used as initial treatment for Stage I disease. By combining treatment with sentinel lymph node biopsy, we were able to accurately determine the stage of disease and thus avoid systematic lymph node dissection and further surgical treatments.
Malignant melanoma of the vagina is very rare tumor so it is necessary to requires the integration of further cases.
KeywordsPrimary malignant melanoma of the vagina Sentinel-node biopsy Vaginal cancer
Primary malignant melanoma of the vagina is an extremely rare condition that affects 1% of women with malignant melanoma and less than 3% of women with malignant tumors of the vagina (Piura et al. 2002; Gokaslan et al. 2005; Nakagawa et al. 2002).
Compared to normal malignant tumors of the skin, hematogenous and lymphogenous metastasis occurs more frequently in malignant melanoma of the vagina.and unfavorable prognosis even in early stage disease (Frumovitz et al. 2010). We report our experience with a patient who presented with primary malignant melanoma and discuss our findings with regard to previously published literature.
No clear evidence of distant metastasis or vaginal wall tumors was obtained by CT examination or pelvic MRI.
Histopathological diagnosis performed using specimens from the previous doctor indicated spindle cell tumor suspicious of leiomyosarcoma, and a vaginal wall tumor resection was qa 1 cm surrounding margin. Histopathology of the resected sample indicated a malignant melanoma-positive surgical margin (Figure 2b, 2c).
In preparation for additional surgery including sentinel lymph node biopsy, we injected m99Tc into the region of the vaginal wall tumor 1 day before surgery, and confirmed the accumulation of m99Tc 2 hours later in the left inguinal to retroperitoneal lymph node (Figure 3b).
A second surgery was performed 35 days after the first operation. We found surgical scars from the previous operation 1 cm from the vaginal opening on the left side. Therefore, the tumor was resected with a 2 cm margin and resection of the vaginal wall was performed. A sentinel lymph node (left superficial inguinal lymph node) biopsy was performed using an isotope, which did not detect lymph node metastasis (0/3) in a rapid histopathological examination. Therefore, pelvic and inguinal lymph node metastasis was not performed.
Histopathological analysis of the resected samples revealed malignant melanoma, and a microscopic distance of 0.3 mm was observed between the resected margin of the vaginal wall and the tumor. This indicated that the resected region did not fall within the safety margin and an additional surgery was scheduled. A third surgery was performed 35 days after the second operation. To ensure adequate vaginal wall resection, we performed an abdominal modified radical hysterectomy followed by a left-side vaginectomy.
Surgical findings: We performed an abdominal modified radical hysterectomy. After processing the anterior layer of the vesico-uterine ligament bilaterally, we separated the bladder from the vaginal wall from the outside of the left abdominal cavity. We then processed the paravaginal tissue on the left side by accessing it from the abdominal side; vaginal wall resection was performed by approaching it from the external genitalia. Finally, we penetrated the abdominal cavity and the left side of the vagina, and removed the left side of the vagina and the uterus together.
The final diagnosis was primary malignant melanoma of the vagina T4bN0M0 Stage IIc (UICC 2009), based on the tumor size of 2 cm, over 4 mm of interstitial invasion, the lack of evidence of metastasis to the inguinal lymph nodes extracted as sentinel lymph nodes, and the lack of evidence of distant metastasis.
DTIC: 120 mg/m2/day, iv.
ACNU: 60 mg/m2/day, iv.
VCR: 0.6 mg/m2/day, iv
Feron: 3,000,000 E/body/day, local injection
Primary malignant melanoma of the vagina is an extremely rare condition that affects 1% of women with malignant melanoma and less than 3% of women diagnosed with malignant tumors of the vagina. Approximately 250 cases have been reported in the literature and 0.026 in 100,000 people are expected to present with this condition each year (Piura et al. 2002; Gokaslan et al. 2005; Nakagawa et al. 2002). Approximately 3% of females have melanocytes (melanin-producing pigment cells) in the basement membrane of the epithelium of the vaginal mucous membrane, which can be the site of onset of primary malignant melanoma of the vagina (Gokaslan et al. 2005). Approximately 80% of cases occur post-menopause with an average age of onset of 60 years, and the primary symptom is vaginal bleeding (Frumovitz et al. 2010). A study showed that 84% of patients are Caucasian (Frumovitz et al. 2010). Most cases occur in the lower third of the vagina on the anterior vaginal wall (Nakagawa et al. 2002). Although malignant melanoma often presents with pigmentation, our patient was amelanotic. Reports suggest that amelanotic cases account for less than 10% of all cases (Nakagawa et al. 2002).
In the determination of the clinical stage of primary malignant melanoma of the vagina, the staging classification of the International Federation of Gynecology and Obstetrics (FIGO), which is used in vaginal cancers, does not combine tumor size and lymph node metastasis. Instead, staging of primary malignant melanoma of the vagina is based on the classification of the Union for International Cancer Control 2009 (UICC), which is used for the staging of malignant melanoma.
Several advanced cases of primary malignant melanoma of the vagina have been reported, and the prognosis is extremely poor even in early stage disease. Frumovitz et al. reported that the 5-year survival rate for Stage I primary malignant melanoma of the skin is 81% compared to 18% for melanoma originating in the vagina. The authors analyzed 37 patients with Stage I primary malignant melanoma of the vagina and reported a 5-year progression-free survival rate of 9.5% and a 5-year overall survival rate of 20.0% (Frumovitz et al. 2010).
Frumovitz et al. reported on the effectiveness of surgical therapies for primary malignant melanoma of the vagina. These authors found that patients treated with only radiation or chemotherapy as initial treatment for Stage I primary malignant melanoma of the skin had an average survival of 8.7 months, compared to 24–32 months for those that also received prior surgical therapies, which was a significant increase (P = 0.01) in survival (Frumovitz et al. 2010).
However, with respect to the surgical methods, they reported no significant differences between patients who underwent lesion excision, radical surgery, or pelvic exenteration (Frumovitz et al. 2010). Pelvic exenteration often presents with surgery-related complications, which prevents it from becoming a standard therapy, especially if adjuvant therapies are considered. The definitiveness of local excision of lesions can be a problem in addition to the possibility of local recurrence associated with this surgical method.
Therapeutic considerations such as the systematic removal of inguinal and pelvic lymph nodes in primary malignant melanoma of the vagina are uncommon; however, lymph node metastasis is a prognostic factor. Therefore, the detection of lymph node metastasis is necessary. However, considering the invasiveness of surgical intervention, operations should be limited as much as possible. In general, sentinel lymph node biopsies are indicated in patients with malignant melanoma and are used frequently in other primary sites (Lens et al. 2002). The MSLT-1 study investigated the effectiveness of sentinel lymph node biopsies, and we performed sentinel lymph node biopsies based on this theoretical background.
To determine whether sentinel lymph node biopsies improved survival rates in all cases of malignant melanoma, a randomized, comparative trial was conducted in collaboration with 17 institutions (MSLT-1). In this trial, 1269 patients with primary tumor thicknesses between 1.2 mm and 3.5 mm were divided into 2 groups consisting of 769 patients receiving sentinel lymph node biopsies and 500 patients receiving primary lesion resection only (dissection was performed after discovery of lymph node metastasis during post-operative periodic observations). The results showed that the 5-year progression free survival rate in patients with biopsies was 78.3 ± 1.3% compared to 73.1 ± 2.1% for those without, which was a significant increase in the former group (P = 0.009, death HR: 0.74) (Morton et al. 2006).
Our study also demonstrated that lymph node dissection should be performed early if sentinel lymph node biopsies reveal metastasis by microscopy, instead of waiting until metastasis is observed during periodic observation after primary tumor resection. However, whether lymph node dissection itself can affect prognosis remains to be elucidated (Morton et al. 2006).
In the present study, we performed sentinel lymph node biopsy of the left superficial inguinal lymph nodes using an isotope. We were able to omit systematic lymph node dissection by confirming the absence of inguinal lymph node metastasis (-) through rapid pathological diagnosis.
Postoperative adjuvant therapy is the treatment of choice in patients with regional lymph node metastasis and primary malignant tumors of the skin larger than 4 mm. Currently, DAV-Feron therapy (DTIC/ACNU/VCR combination therapy with interferon β injection at the site of the operative wound) is the standard therapy for melanoma internationally. A multi-center trial investigated the effectiveness of adjuvant therapy after radical operations for previous-UICC stage II and III patients (thickness >4 mm or positive regional lymph nodes) in Japan. The results showed that compared with historical controls treated with DAV only, the combined therapy significantly improved the 5-year survival rate (65.1% vs. 46.2%; P < 0.05) (Yamamoto & Ishikawa 1996).
We did not detect lymph node metastasis in the present patient; however, we selected DAV-Feron therapy because the tumor was larger than 4 mm.
Other therapies for melanomas with distal metastasis currently include high-dose IL-2 therapy and molecular targeted drugs.
High-dose IL-2 therapy has a response rate of approximately 15% and a complete response rate of 6%; however, it is associated with severe adverse reactions and is therefore not considered beneficial. Nevertheless, long-term, relapse-free survival was reported in a low percentage of patients (approximately 5%) (Atkins et al. 1998).
The molecular targeted drug BAY 43-9006 (sorafenib), a Raf-1 inhibitor, is noteworthy. In addition to inhibiting the MAPK signaling pathway, this drug also inhibits tyrosine kinase receptors associated with angiogenesis such as VEGFR-2, VEGFR-3, PDGFR- β, Flt-3, and c-KIT. In a phase I/II clinical trial, sorafenib combined with carboplatin/paclitaxel achieved impressive results with a partial response rate of 40% and a stable disease (SD) rate of 43%. A phase III clinical trial is currently underway (Strumberg 2005).
The prognosis of mucous membrane-derived malignant melanomas, including those in the vaginal wall, is poor compared to those derived from the skin. Currently, surgical resection has the highest probability of improving the prognosis of patients when used as initial treatment for Stage I disease. By combining treatment with sentinel lymph node biopsy, we were able to accurately determine the stage of disease and thus avoid systematic lymph node dissection and further surgical treatments. We anticipate that post-operative adjuvant DAV-Feron therapy could be combined with molecular targeted drugs such as sorafenib in the future.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
- Atkins MB, Kunkel L, Sznol M, Rosenberg SA (1998) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 9:S11–S14Google Scholar
- Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, Ramirez PT (2010) Primary malignant melanoma of the vagina. Obstet Gynecol 116:1358–1365View ArticleGoogle Scholar
- Gokaslan H, Sismanoğlu A, Pekin T, Kaya H, Ceyhan N (2005) Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol 121:243–248View ArticleGoogle Scholar
- Lens MB, Dawes M, Goodacre T, Newton-Bishop JA (2002) Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 137:458–461Google Scholar
- Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ, MSLT Group (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307–1311View ArticleGoogle Scholar
- Nakagawa S, Koga K, Kugu K, Tsutsumi O, Taketani Y (2002) The evaluation of the sentinel node successfully conducted in a case of malignant melanoma of the vagina. Gynecol Oncol 86:387–389View ArticleGoogle Scholar
- Piura B, Rabinovich A, Yanai-Inbar I (2002) Primary malignant melanoma of the vagina: case report and review of literature. Eur J Gynaecol Oncol 23:195–198Google Scholar
- Strumberg D (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 12:773–784View ArticleGoogle Scholar
- Yamamoto A, Ishikawa K (1996) Clinical study of DAV + IFN-beta therapy (combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta for malignant melanoma. Int J Immunother 12:73–78Google Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.